Search results
Results from the WOW.Com Content Network
The metabolism of metoprolol can vary widely among patients, often as a result of hepatic impairment [9] or CYP2D6 polymorphism. [10] Metoprolol was first made in 1969, patented in 1970, and approved for medical use in 1978. [11] [12] [13] It is on the World Health Organization's List of Essential Medicines. [14] It is available as a generic ...
Glucuronidation occurs mainly in the liver, although the enzyme responsible for its catalysis, UDP-glucuronyltransferase, has been found in all major body organs (e.g., intestine, kidneys, brain, adrenal gland, spleen, and thymus). [3] [4]
The other elimination pathways are less important in the elimination of drugs, except in very specific cases, such as the respiratory tract for alcohol or anaesthetic gases. The case of mother's milk is of special importance. The liver and kidneys of newly born infants are relatively undeveloped and they are highly sensitive to a drug's toxic ...
Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism (from the Greek xenos "stranger" and biotic "related to living beings") is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug ...
[4] [5] It has been estimated that about 5% of atenolol is metabolized. [6] This is in contrast to other beta blockers like propranolol and metoprolol, but is similar to nadolol. [4] In accordance with its lack of hepatic metabolism, the pharmacokinetics of atenolol are not altered in hepatic impairment, unlike the case of propranolol. [5]
[14] [15] [16] Bisoprolol, carvedilol, and sustained-release metoprolol are specifically indicated as adjuncts to standard ACE inhibitor and diuretic therapy in congestive heart failure, although at doses typically much lower than those indicated for other conditions. Beta blockers are only indicated in cases of compensated, stable congestive ...
CYP3A4 is a member of the cytochrome P450 superfamily of enzymes.The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of steroids (including cholesterol), and other lipids.
The progress in β-blocker development led to the introduction of drugs with variety of properties. β-blockers were developed having a relative selectivity for cardiac β1-receptors (for example metoprolol and atenolol), partial adrenergic agonist activity , concomitant α-adrenergic blocking activity (for example labetalol and carvedilol) and ...